Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
Checked against the public recordLast updated Jul 9, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Nuvectis Pharma, Inc.
- Interventions being studied
- Drug: NXP900; Drug: Osimertinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Provide written informed consent. 2. 18 years old or older. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Unresectable, metastatic or locally advanced EGFR-mutated NSCLC. 5. Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting. Exclusion Criteria: 1. Subject's cancer has a known oncogenic driver alteration other than EGFR. 2. Known EGFR mutations that cause resistance to osimertinib 3. Known human epidermal growth factor receptor 2 (HER2) overexpression 4. Any contraindications to treatment with osimertinib
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Maryland Oncology HematologyCalverton, Maryland
- Massachusetts General HospitalBoston, Massachusetts
- Willamette Valley Cancer Institute and Research CenterEugene, Oregon
- UPMC Hillman Cancer CenterPittsburgh, Pennsylvania
- NEXT HoustonHouston, Texas
- NEXT VirginiaFairfax, Virginia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 9, 2026. Always confirm current availability with the study team.